What is the role of cabazitaxel (Jevtana) in the treatment of hormone-refractory prostate cancer?

Updated: Dec 29, 2020
  • Author: Martha K Terris, MD, FACS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print
Answer

Answer

In June 2010, cabazitaxel (Jevtana), a microtubular inhibitor, was approved by the FDA for second-line treatment. This agent is indicated in combination with prednisone for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!